Article Figures & Data
Figures
- Figure 1.
Exclusion criteria.
GAHT = gender-affirming hormone therapy.
- Figure 2.
Cumulative incidence of erythrocytosis over 20-month study period.
Hct = hematocrit.
Tables
Duration of Testosterone Therapy (mon) No. of Patients Followed Incident Cases of Erythrocytosis Probability of Hct in Normal Range Cumulative Incidence of Erythrocytosis Erythrocytosis (Hct >50.4) Baseline 282 0 1.000 0.000 2.0-4.9 282 2 0.993 0.007 5.0-7.9 235 2 0.991 0.016 8.0-10.9 171 2 0.988 0.027 11.0-13.9 126 4 0.968 0.059 14.0-16.9 85 2 0.976 0.083 17.0-19.9 69 3 0.957 0.126 20.0-22.9 38 1 0.974 0.152 23.0-25.9 29 4 0.862 0.290 26.0-28.9 7 1 0.857 0.433 29.0-31.9 3 0 1.000 0.433 Erythrocytosis (Hct >52) Baseline 282 0 1.000 0.000 2.0-4.9 282 0 1.000 0.000 5.0-7.9 237 1 0.996 0.004 8.0-10.9 174 1 0.994 0.010 11.0-13.9 128 0 1.000 0.010 14.0-16.9 88 0 1.000 0.010 17.0-19.9 71 0 1.000 0.010 20.0-22.9 40 0 1.000 0.010 23.0-25.9 31 2 0.935 0.074 26.0-28.9 7 0 1.000 0.074 29.0-31.9 3 0 1.000 0.074 Erythrocytosis (Hct >54) Baseline 282 0 1.000 0.000 2.0-4.9 282 0 1.000 0.000 5.0-7.9 237 0 1.000 0.000 8.0-10.9 174 1 0.994 0.006 11.0-13.9 128 0 1.000 0.006 14.0-16.9 88 0 1.000 0.006 17.0-19.9 71 0 1.000 0.006 20.0-22.9 40 0 1.000 0.006 23.0-25.9 31 0 1.000 0.006 26.0-28.9 7 0 1.000 0.006 29.0-31.9 3 0 1.000 0.006 Hct = hematocrit.
